Vitae Pharmaceuticals is a clinical stage biotechnology company pursuing “difficult-to drug” targets
As an innovative clinical stage biotechnology company, we are developing a robust and growing portfolio of novel product candidates generated by Contour®, our proprietary computationally-based SBDD platform. Our team of accomplished scientists utilizes Contour® to rapidly discover highly potent and selective product candidates for validated targets against which the industry has traditionally struggled to develop drugs. We address multiple disease areas including autoimmune disorders such as psoriasis and atopic dermatitis.
Vitae Pharmaceuticals is discovering and developing drugs for diseases with significant unmet medical needs
- Our most advanced wholly-owned product include VTP-43742 for the treatment of various autoimmune disorders including psoriasis and VTP-38543 for the treatment of atopic dermatitis. VTP-43742 recently completed a positive phase 2a trial in March 2016 and VTP-38543 began a phase 2a trial in December 2015 with data expected in the second half of 2016.
- We are also leveraging Contour® in new discovery programs.
Our Management Team, Board of Directors, and scientific advisors have significant experience developing and commercializing drugs in multiple therapeutic areas for both large and small pharmaceutical companies and biotechnology companies. We believe that compounds discovered by Contour® have the potential to transform treatment for patients with autoimmune disorders such as psoriasis, atopic dermatitis, and other important disease areas.